Monte Rosa Therapeutics, Inc. (GLUE) Operating cash flow 2020–2025
Monte Rosa Therapeutics, Inc. (GLUE) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$22.8MFY2025 · since FY2020: -$23.1M → -$22.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$22.8M | -154.3% |
| FY2024 | $42.0M | +195.9% |
| FY2023 | -$43.8M | +52.6% |
| FY2022 | -$92.5M | -55.8% |
| FY2021 | -$59.4M | -157.5% |
| FY2020 | -$23.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GLUE financial trends
GLUE RevenueGLUE Net incomeGLUE Net marginGLUE Gross profitGLUE Gross marginGLUE Operating incomeGLUE Operating marginGLUE Free cash flowGLUE Capital expendituresGLUE Return on equityGLUE Stock buybacksGLUE Dividends paidGLUE Total assetsGLUE Total liabilitiesGLUE Shareholders’ equityGLUE overview →